替比夫定联合TACE治疗原发性肝癌的疗效观察.docVIP

精品论文 参考文献 替比夫定联合TACE治疗原发性肝癌的疗效观察 贾文玲1 王凤梅1 　　(甘肃省武威肿瘤医院肝病科 , 甘肃733000） 　　摘要：目的：探讨替比夫定联合TACE治疗原发性肝癌的疗效。方法：选择2009-2013年在我科住院的原发性肝癌患者（II期）67例，随机分为治疗组与对照组，治疗组37例，给予替比夫定(600mg/日，口服)联合超选择性肝动脉灌注化疗栓塞术（transcatheter arterialchemoembolization，TACE）及常规保肝治疗，对照组30例，用TACE治疗及常规保肝治疗，两组患者经治疗后1周及1月均常规进行ALT、TB检查，比较2组患者的肝功能变化情况。结果：治疗组患者的ALT、TB升高率均低于对照组（Plt;0.05）。结论：替比夫定联合TACE治疗原发性肝癌与单用TACE治疗的患者血ALT、TB之间的差异有统计学意义。 　　关键词：原发性肝癌 TACE 替比夫定 　　The Clinical Observation of Telbivudine Tablets Combined with TACE for Treating Primary lLiver Carcinoma 　　JIA wen-ling,WANG feng-mei, 　　Hepatic Disease Department ,Wuwei Tumor Hospital,Wuwei 733000,Gansu,China 　　【Abstract】Objective: To discuss the clinical effects of Telbivudine Tablets combined with TACE for treating Primary liver carcinoma(PLA). Methods: The clinical data of 67 PLA patients during 2009-2013 were collected and analyzed.They were divided into treatment group and control group.The treatment group has 34 patients ,and they were given the Telbivudine Tablets(600mg per day,po,) combined with TACE for treating PLA.The control group has 34 patients ,and they has the hepatic artery chemoembolization treatment(TACE)only,and then we observe the status of ALT\TB after one week and one month. Results:the treatment group has a lower level of ALT/TB than the control group,the two groups has a significant difference (Plt;0.05);. Conclusion: The Clinical efficiency of Telbivudine Tablets combined with TACE for treating Primary liver carcinoma is better than the pure TACE. 　　Key words: Primary Liver Carcinoma,TACE,Telbivudine Tablets 　　原发性肝癌是一种高度恶性的肿瘤，据统计，全国每年有137000例肝癌被确诊，大约占全世界肝癌患者总数40%[1]。在我国多继发于慢性乙型肝炎、肝硬化患者，临床中采取以手术、化疗、放射治疗、介入治疗、分子靶向治疗等多学科、综合治疗方式。对于手术不能切除的肝癌，超选择性肝动脉灌注化疗栓塞术（transcatheter arterialchemoembolization，TACE）作为一种重要的治疗手段，使原发性肝癌患者的预后及生存期得到了很大的提高。肝功能的损伤是TACE的主要并发症，如何保障患者的治疗安全，就成了一个我们需要思考的课题。我科自2009年到2013年间对住院进行TACE治疗的原发性肝癌患者合并乙型肝炎患者联合给予替比夫定(Telbivudine Tablets)600mg/日抗病毒治疗，减少了肝功能损伤的发生率，提高了治疗的安全性，现总结报告如下: 　　1资料与方法 　　1.1 一般资料 　　随机选取